Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL538119 | 0.96 | — | — | |
| Diethylamine SCHEMBL11564718 | 0.92 | TP53 (0.67) | TP53TSHRALDH1A1CYP2C19MEN1 | |
| Diethylamine SCHEMBL28088004 | 0.92 | — | — | |
| Diethylamine SCHEMBL28184500 | 0.92 | — | — | |
| Diethylamine SCHEMBL27872307 | 0.92 | — | — | |
| Diethylamine SCHEMBL11582370 | 0.92 | TP53 (0.67) | TP53TSHRALDH1A1CYP2C19MEN1 | |
| Diethylamine SCHEMBL509438 | 0.91 | — | — | |
| Diethylamine SCHEMBL11565851 | 0.87 | TP53 (0.73) | TP53TSHRALDH1A1CYP2C19MEN1 | |
| Diethylamine SCHEMBL11583123 | 0.87 | TP53 (0.73) | TP53TSHRALDH1A1CYP2C19MEN1 | |
| Diethylamine SCHEMBL4046893 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107543872-B | Method for separating and determining edoxaban tosylate hydrate and isomer impurities thereof by chiral high performance liquid chromatography | 南京长澳医药科技有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-118147101-A | Method for preparing moxifloxacin intermediate by enzyme catalysis | 湖州颐盛生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117368336-A | Impurity detection method for tamsulosin hydrochloride preparation composition | 昆明积大制药股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-107543872-B | Method for separating and determining edoxaban tosylate hydrate and isomer impurities thereof by chiral high performance liquid chromatography | 南京长澳医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | TP53 582/4885TSHR 2398/4885ALDH1A1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.